transcriptomics
(7)
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Aqtual, Inc.
Aqtual, Inc. is a Hayward, California precision medicine company that reads epigenetics, gene regulation and transcriptomics from a single blood draw. Its proprietary active-chromatin cell-free DNA (cfDNA) platform captures circulating chromatin to survey hundreds of thousands of regulatory sites, integrating DNA, epigenetic regulation and protein-DNA binding in one blood-based assay. The company is first commercializing a test that predicts which therapy will work for rheumatoid arthritis patients, with a broader pipeline spanning oncology, immunology, cardiovascular, metabolic and neurological disease. Aqtual has raised roughly $47M to date, including a $31M Series B in July 2025.
Fauna Bio
Fauna Bio is an AI-driven drug discovery company that mines roughly 100 million years of evolved disease resistance in mammals to find new human therapies. Founded in 2018 in the San Francisco Bay Area, it combines comparative genomics, a proprietary animal biobank, and machine learning - through its Convergence and Fauna Brain platforms - to translate the biology of hibernators and other resilient species into drug targets for conditions like obesity, heart failure, neurodegeneration, and retinal disease. Its work has attracted a partnership with Eli Lilly worth up to $494 million.
Gordian Biotechnology
Gordian Biotechnology is a South San Francisco in vivo drug discovery company building a high-throughput screening platform that tests hundreds of gene therapies simultaneously inside animals that naturally develop age-related diseases. By pairing 'patient avatar' models with single-cell transcriptomics and machine learning (a stack the company calls Mosaic Screening + Pythia), Gordian aims to predict human clinical outcomes earlier and cure complex diseases of aging.
Tim Sweeney
Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.
Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Samuel Rodriques
Samuel Rodriques is a physicist-turned-bioengineer and co-founder and CEO of Edison Scientific, the AI-driven scientific discovery company behind Kosmos - an AI scientist that reportedly condenses six months of PhD-level research into a single day. A MIT PhD and Hertz Fellow who invented implosion fabrication and pioneered spatial transcriptomics, Rodriques left the Francis Crick Institute to co-found FutureHouse (funded by Eric Schmidt) in 2023, then spun it into for-profit Edison Scientific, which raised a $70M seed round at a $250M valuation in December 2025. Named to Time 100 AI in 2025, he is on a mission to cure all diseases by mid-century through AI-accelerated science.